Abstract:δ opioid receptors (DORs) hold potential as a target for neurologic and psychiatric disorders, yet no DOR agonist has proven efficacious in critical phase II clinical trials. The exact reasons for the failure to produce quality drug candidates for the DOR are unclear. However, it is known that certain DOR agonists can induce seizures and exhibit tachyphylaxis. Several studies have suggested that those adverse effects are more prevalent in delta agonists that share the (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80)/4-[(αR*)-α-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide chemotype. There is a need to find novel lead candidates for drug development that have improved pharmacological properties to differentiate them from the current failed delta agonists. Our objective in this study was to identify novel DOR agonists. We used a β-arrestin assay to screen a small G-protein coupled receptors (GPCR)-focused chemical library. We identified a novel chemotype of DOR agonists that appears to bind to the orthosteric site based of docking and molecular dynamic simulation. The most potent agonist hit compound is selective for the DOR over a panel of 167 other GPCRs, is slightly biased toward G-protein signaling and has anti-allodynic efficacy in a complete Freund's adjuvant model of inflammatory pain in C57BL/6 male and female mice. The newly discovered chemotype contrasts with molecules like SNC80 that are highly efficacious β-arrestin recruiters and may suggest this novel class of DOR agonists could be expanded on to develop a clinical candidate drug. SIGNIFICANCE STATEMENT: δ opioid receptors are a clinical target for various neurological disorders, including migraine and chronic pain. Many of the clinically tested delta opioid agonists share a single chemotype, which carries risks during drug development. Through a small-scale high-throughput screening assay, this study identified a novel δ opioid receptor agonist chemotype, which may serve as alternative for the current analgesic clinical candidates.

Discovery of 3‐(2‐aminoethyl)‐thiazolidine‐2,4‐diones as a Novel Chemotype of Sigma‐1 Receptor Ligands

Exploring Structural Requirements for Sigma-1 Receptor Linear Ligands: Experimental and Computational Approaches

Discovery of Thiadiazole Amides As Potent, S1p(3)-Sparing Agonists of Sphingosine-1-Phosphate 1 (s1p(1)) Receptor

Discovery of N-cyclobutylaminoethoxyisoxazole Derivatives As Novel Sigma-1 Receptor Ligands with Neurite Outgrowth Efficacy in Cells

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Synthesis and Biological Evaluation of Novel 6,7-Dihydro-5h-cyclopenta[d]pyrimidine and 5,6,7,8-Tetrahydroquinazoline Derivatives As Sigma-1 (σ1) Receptor Antagonists for the Treatment of Pain.

Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management

Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases

Discovery of Novel 1,2,4-Thiadiazole Derivatives As Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).

From Α4β2 Nicotinic Ligands to the Discovery of Σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.

Synthesis and Biological Evaluation of a Novel Sigma-1 Receptor Antagonist Based on 3,4-Dihydro-2(1h)-quinolinone Scaffold As a Potential Analgesic.

Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype

Synthesis and Biological Evaluation of σ1 Receptor Ligands Based on Phenyl-1,2,4-oxadiazole Derivatives.

Studies on the affinity of 6-[(n-(cyclo)aminoalkyl)oxy]-4 H-chromen-4-ones for sigma 1/2 receptors

Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.

Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy

Synthesis and Biological Evaluation of Novel Σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

SKF83959 is a Potent Allosteric Modulator of Sigma-1 Receptor

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

3D-QSAR Studies on Thiazolidin-4-one S1P1 Receptor Agonists by CoMFA and CoMSIA

The Sigma Enigma: A Narrative Review of Sigma Receptors